The disclosure relates to methods for treating galactosemia and manifestations of galactosemia using aldose reductase inhibitors.

The disclosure relates to methods for treating galactosemia and manifestations of galactosemia using aldose reductase inhibitors.

This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.

This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.

The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Procedures for inhibiting hormone receptor activation include administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions. Procedures for treating prostate cancer or breast cancer include administering to a subject having prostate cancer or breast cancer a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions.

A small molecule TNF-α inhibitor is disclosed. The compound has an activity of inhibiting the formation of a TNF-α homotrimer by specifically binding to the binding cavity of a TNF-α homodimer. A composition containing the compound as well as uses of the compound and the composition in preventing or treating autoimmune diseases and/or inflammatory diseases are disclosed. Extracellular inactivation of TNF-α through protein-protein interface destruction is the most innovative and effective method for alleviating chronic systemic inflammatory states, and TIM series compounds, which have better efficacy and lower toxicity than those of existing TNF inhibitors and have oral bioavailability, can be effectively used as leading anti-inflammatory molecules.

A small molecule TNF-α inhibitor is disclosed. The compound has an activity of inhibiting the formation of a TNF-α homotrimer by specifically binding to the binding cavity of a TNF-α homodimer. A composition containing the compound as well as uses of the compound and the composition in preventing or treating autoimmune diseases and/or inflammatory diseases are disclosed. Extracellular inactivation of TNF-α through protein-protein interface destruction is the most innovative and effective method for alleviating chronic systemic inflammatory states, and TIM series compounds, which have better efficacy and lower toxicity than those of existing TNF inhibitors and have oral bioavailability, can be effectively used as leading anti-inflammatory molecules.

A pharmaceutical composition comprising: a) an effective amount of an Inhibitors of Apoptosis Proteins (IAP) inhibitor, wherein the IAP inhibitor is represented by formula (I): or a pharmaceutically acceptable salt thereof, the definitions of each variable are provided herein; b) an effective amount of a second inhibitor, wherein the second inhibitor is a poly ADP ribose polymerase (PARP) inhibitor or a mitogen-activated protein kinase kinase (MEK) inhibitor; and a pharmaceutically acceptable carrier or diluent.

##STR00001##